A one-month real-world review of the Blackmagic PYXIS 12K. Image quality, RAW workflow, pros, cons, and who this full-frame camera is really for.

Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.

As of Thursday, December 18, Pyxis Oncology, Inc.’s PYXS share price has dipped by 53.39%, which has investors questioning if ...

Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...

ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kg Updated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC ...

Well, this is a nice surprise to wake up to if you’re a Blackmagic PYXIS (6K or 12K) or URSA Broadcast G2 owner. The latest ...

Having recently trimmed back its pipeline to a sole cancer candidate, Pyxis Oncology has now reduced its head count to match. The Boston biotech is shrinking its workforce by "approximately" 20%, it ...

Pyxis Oncology, Inc. (PYXS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...

Lara Sullivan, Pyxis Oncology CEO, joins Yahoo Finance to discuss the biotech company going public and its oncology treatments for patients with difficult-to-treat cancer. JARED BLIKRE: Well, an IPO ...

The monotherapy trial suggested a confirmed overall-response rate of 46% and a disease-control rate of 93%. In combination with Keytruda, the confirmed overall-response rate was 71% and the ...

The round is backed by Shift4Good, Motion Ventures, SG Growth Capital & Mol Plus Proceeds will be channelled towards scaling ...

Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...